Philip J. Bergman

Dr. Philip J. Bergman


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Veterinary Clinics of North America: Small Animal Practice
Verified
Journal Article
Closed access
PBPhilip J. Bergman
Philip J. Bergman

28 December 2023 in Veterinary Clinics of North America: Small Animal Practice
Verified
Journal Article
Closed access
PBPhilip J. Bergman
Philip J. Bergman

3 September 2018 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
MMMargaret Musser
Margaret Musser
KTKathryn L. Taikowski
Kathryn L. Taikowski
CJChad Johannes
Chad Johannes
PBPhilip J. Bergman
Philip J. Bergman
Effective treatment options for inoperable, metastatic, or recurrent canine pheochromocytomas are lacking. In humans, specific germline mutations exist that drive the development of pheochromocytomas. Pharmaceutical blockade of these abnormalities with small molecule inhibitors are an effective treatment strategy. Similar mutations may exist in the dog, and thus, treatment with similar small molecule inhibitors may provide a survival advantage. The purpose of this study was to assess the role of toceranib phosphate in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas. Retrospectively, medical records of dogs that had a diagnosis or suspect diagnosis of a pheochromocytoma were reviewed for information regarding response to toceranib phosphate and overall outcome. Five dogs were identified that fit the inclusion criteria. All five experienced clinical benefit (1 partial response, 4 stable disease). Progression-free interval (PFI) for the dog with the partial response was 61 weeks. PFI for the two dogs with stable measurable disease were 36 weeks and 28 weeks. PFI in the two dogs with stable metastatic disease were at least 11 weeks and 18 weeks. Based on this limited series of dogs, the results suggest that toceranib may have biological activity in dogs with primary and metastatic pheochromocytomas. Larger studies are needed to define the use and response to toceranib in dogs with gross, microscopic, and metastatic pheochromocytoma.

23 August 2016 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
CSCheryl Stroud
Cheryl Stroud
IDIgor Dmitriev
Igor Dmitriev
EKElena Kashentseva
Elena Kashentseva
JBJeffrey N Bryan
Jeffrey N Bryan
DCDavid Curiel
David Curiel
RHRobert J Harman
Robert J Harman
Click on the article title to read more.

1 March 2018 in Veterinary Clinics of North America: Small Animal Practice
Verified
Journal Article
Closed access
PBPhilip J. Bergman
Philip J. Bergman

18 July 2024 in Viruses
Verified
Journal Article
Open access
PDF file
AKAnne Kimmerlein
Anne Kimmerlein
TMTalon S. McKee
Talon S. McKee
PBPhilip J. Bergman
Philip J. Bergman
ISIrina Sokolchik
Irina Sokolchik
CLChristian M. Leutenegger
Christian M. Leutenegger
Recent emerging zoonotic disease outbreaks, such as that of SARS-CoV-2, have demonstrated the need for wider companion animal disease surveillance. We tested 1000 dogs and cats belonging to employees of a US veterinary hospital network that were exposed to human COVID-19 cases in the household between 1 January 2020 and 10 March 2022 for SARS-CoV-2 and surveyed their owners about clinical signs and risk factors. The seropositivity was 33% for 747 dogs and 27% for 253 cats. Pet seropositivity correlated with the US human case rates over time, exhibiting peaks corresponding with the major COVID-19 surges. Antibodies persisted longer than previously documented (828 days in dogs; 650 days in cats). Increasing age and duration of proximity to infected people were associated with increased seropositivity in dogs but not cats. Cats were more likely to have clinical signs, but an association between seropositivity and the presence of clinical signs was not found in either species.